Sales for the quarter of $3.03M, up 42.5% from the prior year period o Growth reflects Cardiocel®’s increasing global availability and traction o CardioCel® now in 110 centres globally Cash balance at 30 September 2015 of $16.7M Initiated a key aortic heart valve reconstruction post-market clinical study using CardioCel® at leading global heart centres HSV-2 Phase II nearing completion, with interim results due at end of this calendar year Manufacturing of the HPV therapeutic vaccine completed in preparation for Ian Frazer’s next HPV product heading into the clinic Admedus Vaccines rebrands as Admedus Immunotherapies
(20min delay)